There is no known specific antidote for Oncotronee Sterile Concentrate. Haemopoietic, gastrointestinal, hepatic or renal toxicity may be seen, depending on the dosage given and the physical condition of the patient. In cases of overdosage patients should be monitored closely and management should be symptomatic and supportive.
Fatalities have occurred on rare occasions as a result of severe leucopenia with infection in patients accidentally given single bolus injections of Oncotronee at over ten times the recommended dosage. Oncotronee Sterile Concentrate is extensively tissue-bound and peritoneal dialysis or haemodialysis is unlikely to be effective in managing overdose.
FOR INTRAVENOUS USE ONLY.
Oncotronee Sterile Concentrate is contraindicated in patients who have demonstrated prior hypersensitivity to Oncotronee hydrochloride, other anthracylines or any of its components. Use in patients with profound bone marrow suppression is a relative contraindication depending on the clinical circumstances.
Oncotronee Sterile Concentrate should not be used during pregnancy or lactation.
Oncotronee Sterile Concentrate must not be mixed in the same infusion as heparin since a precipitate may form.
It is recommended that Oncotronee Sterile Concentrate not be mixed in the same infusion with other drugs, as specific compatibility data are not available.
Cardiac monitoring should also be performed in patients without identifiable risk factors during therapy exceeding 160 mg/m2 of Oncotronee, or during extended treatment.
Careful supervision is recommended when treating patients with hepatic insufficiency.
Topoisomerase II inhibitors, including Oncotronee hydrochloride, when used concomitantly with other antineoplastic agents (particularly anthracyclines) and/or radiotherapy, have been associated with the development of Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndrome (MDS). Treatment with Oncotronee alone has also been associated with an increased risk of development of secondary acute myeloid leukaemia (see 4.8 Undesirable effects).
Sulphites can cause allergic-type reactions including anaphylactic symptoms and bronchospasm in susceptible people, especially those with a history of asthma or allergy.
Immunisation may be ineffective when given during Oncotronee therapy. Immunisation with live virus vaccines are generally not recommended.
There is no experience with the administration of Oncotronee Sterile Concentrate other than by the intravenous route. Safety for intrathecal use has not been established.
Precautions for use
Oncotronee is an active cytotoxic drug which should be used by clinicians who are familiar with the use of antineoplastic agents and have the facilities for regular monitoring of clinical, haematological and biochemical parameters during and after treatment.
Full blood counts should be undertaken serially during a course of treatment. Dosage adjustments may be necessary based on these counts (see Dosage section).
4.5 Interaction with other medicinal products and other forms of interactionAnimal data suggest that if used in combination with other antineoplastic agents, additive myelosuppression may be expected. This has been supported by available clinical data on combination regimens. When used in combination regimens, the initial dose of Oncotronee Sterile Concentrate should be reduced by 2-4 mg/m2 below the dose recommended for single agent usage. (see Posology and method of administration).
Combining Oncotronee with potentially cardiotoxic drugs (anthracyclines) increases the risk of cardiac toxicity. The product must be used with caution in combination with immunosuppressive chemotherapy.
4.6 Pregnancy and lactationThere are no adequate and well-controlled studies in pregnant women. Oncotronee should not normally be administered to patients who are pregnant. If the drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential hazard to the fetus. Women of childbearing potential and their partners should be advised to avoid becoming pregnant and use effective contraception during therapy and for at least six months after cessation of therapy.
Oncotronee is excreted in human milk and significant concentrations (18 ng/ml) have been reported for 28 days after the last administration. Because of the potential for serious adverse reactions in infants from Oncotronee, breast-feeding should be discontinued before starting treatment.
4.7 Effects on ability to drive and use machinesNot applicable.
4.8 Undesirable effectsSerious or Life Threatening Reactions:
Blood and lymphatic system disorders: Some degree of leucopenia is to be expected following recommended doses of Oncotronee. With the single dose every 21 days, suppression of WBC count below 1000/mm3 is infrequent. Leucopenia is usually transient reaching its nadir at about 10 days after dosing with recovery usually occurring by the 21st day. Thrombocytopenia and anaemia occur less frequently. Myelosuppression may be more severe and prolonged in patients who have had extensive prior chemotherapy or radiotherapy or in debilitated patients.
Cardiac disorders: Congestive heart failure may occur during therapy with Oncotronee, or months to years after the end of treatment (see 4.4 Special Warnings and Special Precautions for Use). Some cases have been fatal. Treatment with digoxin and/or diuretics has been reported to be effective.
Other cardiovascular effects, which have been of clinical significance include decreased left ventricular ejection fraction, ECG changes and acute arrhythmia.
In patients with leukaemia an increase in the frequency of adverse cardiac events has been observed. The direct role of Oncotronee in these cases is difficult to assess, since some patients had received prior therapy with anthracyclines and since the clinical course in leukaemic patients is frequently complicated by anaemia, fever, sepsis and intravenous fluid therapy. Cardiomyopathy has been reported in rare instances.
Other Undesirable Effects:
Hepato-biliary disorders and Renal and urinary disorders: Oncotronee Sterile Concentrate may impart a blue-green colouration to the urine for 24 hours after administration, and patients should be advised to expect this during active therapy. Increased liver enzyme levels (with occasional reports of severe impairment of hepatic function in patients with leukaemia). Hyperuricaemia has also been reported. Elevated serum creatinine and blood urea nitrogen levels have been reported.
Skin and subcutaneous tissue disorders: Rash, onycholysis, blue discolouration of skin and nails and nail dystrophy has been reported occasionally. Alopecia may occur, but is most frequently of minimal severity and reversible on cessation of therapy
Eye Disorders: Reversible blue colouration of the sclerae has been reported. Conjunctivitis.
Respiratory disorders: Dyspnoea.
Gastrointestinal Disorders: Diarrhoea, anorexia, constipation, gastrointestinal bleeding, abdominal pain, stomatitis and mucositis. The most commonly encountered side effects are nausea and vomiting, although in the majority of cases these are mild and transient.
Neoplasms: Secondary acute myeloid leukaemia (see 4.4 Special Warnings and Special Precautions for Use)
General disorders and administration site conditions: Fever, fatigue and weakness.
Extravasation at the infusion site has been reported, which may result in erythema, swelling, pain, burning and/or blue discolouration of the skin. Extravasation can result in tissue necrosis with resultant need for debridement and skin grafting. Phlebitis has also been reported at the site of infusion.
Nervous system disorders: Altered taste. Non-specific neurological side effects such as somnolence and mild paraesthesia have been reported.
Metabolism and nutrition disorders: Tumour lysis syndrome (characterised by hyperuricaemia, hyperkalaemia, hyperphosphataemia and hypocalcaemia) has been observed rarely during single-agent chemotherapy with Oncotronee, as well as during combination chemotherapy.
Psychiatric disorders: Confusion, anxiety.
Reproductive system and breast disorders: Amenorrhoea.
In patients with leukaemia, the pattern of side-effects is generally similar, although there is an increase in both frequency and severity, particularly of stomatitis and mucositis. Nevertheless, overall, patients with leukaemia tolerate treatment with Oncotronee well.
Immune system disorders: Allergic reaction.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via
United Kingdom
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard
Ireland
HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
e-mail: [email protected]
Animal pharmacokinetic studies in rats, dogs and monkeys given radiolabelled Oncotronee indicate rapid, extensive dose proportional distribution into most tissues.
Oncotronee does not cross the blood-brain barrier to any appreciable extent. Distribution into testes is relatively low. In pregnant rats the placenta is an effective barrier.
Plasma concentrations decrease rapidly during the first two hours and slowly thereafter. Animal data established biliary excretion as the major route of elimination. In rats, tissue elimination half-life of radioactivity ranged from 20 days to 25 days as compared with plasma half-life of 12 days. Oncotronee is not absorbed significantly in animals following oral administration.
Oncotronee is indicated in the treatment of metastatic breast cancer, non-Hodgkin's lymphoma and adult acute non-lymphocytic leukaemia.
Oncotronee has also been used in the palliation of non-resectable primary hepatocellular carcinoma.
ATC Code: L01D B07
Although its mechanism of action has not been determined, Oncotronee is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.
Pharmacokinetic studies in patients following intravenous administration of Oncotronee demonstrated a triphasic plasma clearance. Distribution to tissues is rapid and extensive. Elimination of the drug is slow with a mean half-life of 12 days (range 5-18) and persistent tissue concentrations. Similar estimates of half-life were obtained from patients receiving a single dose of Oncotronee every 21 days and patients dosed on 5 consecutive days every 21 days.
Oncotronee is excreted via the renal and hepatobiliary systems. Only 20-32% of the administered dose was excreted within the first five days after dosing (urine 6-11%, faeces 13-25%). Of the material recovered in the urine 65% was unchanged Oncotronee and the remaining 35% is primarily comprised of two inactive metabolites and their glucuronide conjugates. Approximately two thirds of the excretion occurred during the first day.
Special warnings
There may be an increased risk of leukaemia when Oncotronee is used as adjuvant treatment of non-metastatic breast cancer. In the absence of sufficient efficacy data, Oncotronee must not be used as adjuvant treatment of non-metastatic breast cancer.
Oncotronee should be used with caution in patients with myelosuppression or poor general condition.
Cases of functional cardiac changes, including congestive heart failure and decreases in left ventricular ejection fraction have been reported during Oncotronee therapy (see 4.8 Undesirable effects). These cardiac events have occurred most commonly in patients who have had prior treatment with anthracyclines, prior mediastinal/thoracic radiotherapy, or in patients with pre-existing heart disease. The concomitant administration of other cardiotoxic drugs may also increase the risk of cardiac toxicity. It is recommended that patients in these categories are treated with Oncotronee at full cytotoxic dosage and schedule. However, added caution is required in these patients and careful regular cardiac examinations are recommended from the initiation of treatment.
Cardiac monitoring should also be performed in patients without identifiable risk factors during therapy exceeding 160 mg/m2 of Oncotronee, or during extended treatment.
Careful supervision is recommended when treating patients with hepatic insufficiency.
Topoisomerase II inhibitors, including Oncotronee hydrochloride, when used concomitantly with other antineoplastic agents (particularly anthracyclines) and/or radiotherapy, have been associated with the development of Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndrome (MDS). Treatment with Oncotronee alone has also been associated with an increased risk of development of secondary acute myeloid leukaemia (see 4.8 Undesirable effects).
Sulphites can cause allergic-type reactions including anaphylactic symptoms and bronchospasm in susceptible people, especially those with a history of asthma or allergy.
Immunisation may be ineffective when given during Oncotronee therapy. Immunisation with live virus vaccines are generally not recommended.
There is no experience with the administration of Oncotronee Sterile Concentrate other than by the intravenous route. Safety for intrathecal use has not been established.
Precautions for use
Oncotronee is an active cytotoxic drug which should be used by clinicians who are familiar with the use of antineoplastic agents and have the facilities for regular monitoring of clinical, haematological and biochemical parameters during and after treatment.
Full blood counts should be undertaken serially during a course of treatment. Dosage adjustments may be necessary based on these counts (see Dosage section).
Not applicable.
Posology
Metastatic breast cancer, Non-Hodgkin's lymphoma, Hepatoma:
Single Agent Dosage: The recommended initial dosage of Oncotronee as a single agent is 14 mg/m2 of body surface area, given as a single intravenous dose which may be repeated at 21-day intervals. A lower initial dosage (12 mg/m2 or less) is recommended for patients with inadequate bone marrow reserves e.g. due to prior chemotherapy or poor general condition.
Dosage modification and the timing of subsequent doses should be determined by clinical judgement depending on the degree and duration of myelosuppression. For subsequent courses the prior dose can usually be repeated if white blood cell and platelet counts have returned to normal levels after 21 days. The following table is suggested as a guide to dosage adjustment in the treatment of metastatic breast cancer, non-Hodgkin's lymphoma and hepatoma according to haematological nadir (which usually occurs about 10 days after dosing).
| Nadir after prior dose | ||||
| WBC (per mm3) | Platelets (per mm3) | Time to recovery | Subsequent dose after adequate haematological recovery | |
| >1,500 | AND | >50,000 | ≤21 days | Repeat prior dose after recovery, or increase by 2 mg/m2 if myelosuppression is not considered adequate |
| >1,500 | AND | >50,000 | >21 days | Withhold until recovery then repeat prior dose |
| <1,500 | OR | <50,000 | Any duration | Decrease by 2 mg/m2 from prior dose after recovery |
| <1,000 | OR | <25,000 | Any duration | Decrease by 4 mg/m2 from prior dose after recovery |
Combination Therapy: Oncotronee has been given as part of combination therapy. In metastatic breast cancer, combinations of Oncotronee with other cytotoxic agents including cyclophosphamide and 5-fluorouracil, or methotrexate and mitomycin C, have been shown to be effective. Reference should be made to the published literature for information on dosage modifications and administration. Oncotronee has also been used in various combinations for non-Hodgkin's lymphoma, however data are presently limited and specific regimens cannot be recommended.
As a guide, when Oncotronee is used in combination chemotherapy with another myelosuppressive agent, the initial dose of Oncotronee should be reduced by 2-4 mg/m2 below the doses recommended for single agent use. Subsequent doses, as outlined in the table above, depend on the degree and duration of myelosuppression.
Adult acute non-lymphocytic leukaemia:
Single Agent Dosage in Relapse: The recommended dosage for remission induction is 12 mg/m2 of body surface area, given as a single intravenous dose daily for five consecutive days (total of 60 mg/m2). In clinical studies with a dosage of 12 mg/m2 daily for 5 days, patients who achieved a complete remission did so as a result of the first induction course.
Combination Therapy: Oncotronee has been used in combination regimens for the treatment of acute non-lymphocytic leukaemia (ANLL). Most clinical experience has been with Oncotronee combined with cytarabine. This combination has been used successfully for primary treatment of ANLL as well as in the treatment of relapse.
An effective regimen for induction in previously untreated patients has been Oncotronee 10-12 mg/m2 IV for 3 days combined with cytarabine 100 mg/m2 IV for 7 days (by continuous infusion). This is followed by second induction and consolidation courses as thought appropriate by the treating clinician. In clinical studies, duration of therapy in induction and consolidation courses with Oncotronee have been reduced to 2 days, and that of cytarabine to 5 days. However, modification to the above regimen should be carried out by the treating clinician depending on individual patient factors.
Efficacy has also been demonstrated with Oncotronee in combination with etoposide in patients who had relapsed or who were refractory to primary conventional chemotherapy. The use of Oncotronee in combination with etoposide, as with other cytotoxics, may result in greater myelosuppression than with Oncotronee alone.
Reference should be made to the published literature for information on specific dosage regimens. Oncotronee should be used by clinicians experienced in the use of chemotherapy regimens. Dosage adjustments should be made by the treating clinician as appropriate, taking into account toxicity, response and individual patient characteristics. As with other cytotoxic drugs, Oncotronee should be used with caution in combination therapy until wider experience is available.
Paediatrics: The safety and efficacy of Oncotronee in paediatric patients have not been established.
Method of administration
FOR INTRAVENOUS USE ONLY.
Dilute the required volume of Oncotronee Sterile Concentrate to at least 50 ml in either of the following infusion solutions: sodium chloride 0.9%, glucose 5%, or sodium chloride 0.18% and glucose 4%. Use Leur-lock fittings on all syringes and sets. Large bore needles are recommended to minimise pressure and the possible formation of aerosols. The latter may also be reduced by the use of a venting needle.
Administer the resulting solution over not less than 3 minutes via the tubing of a freely running intravenous infusion of the above fluids. Oncotronee should not be mixed with other drugs in the same infusion.
If extravasation occurs the administration should be stopped immediately and restarted in another vein. The non-vesicant properties of Oncotronee minimise the risk of severe local reaction following extravasation.
Single use only. Discard any unused contents.
Spillage disposal: The following clean-up procedure is recommended if Oncotronee Sterile Concentrate is spilled on equipment or environmental surfaces. Prepare a 50% solution of fresh concentrated bleach (any recognised proprietary brand containing either sodium or calcium hypochlorite) in water. Wet absorbent tissues in the bleach solution and apply the wetted tissues to the spillage. The spillage is deactivated when the blue colour has been fully discharged. Collect up the tissues with dry tissues. Wash the area with water and soak up the water with dry tissues. Appropriate protective equipment should be worn during the clean-up procedure. All Oncotronee contaminated items (e.g. syringes, needles, tissues etc.) should be treated as toxic waste and disposed of accordingly. Incineration is recommended.
